Renal Cell Carcinoma Metastatic Clinical Trials

7 recruiting

Renal Cell Carcinoma Metastatic Trials at a Glance

9 actively recruiting trials for renal cell carcinoma metastatic are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Beijing, Chengdu, and Bergen. Lead sponsors running renal cell carcinoma metastatic studies include Niels Fristrup, Neomorph, Inc, and Kidney Cancer Research Bureau.

Browse renal cell carcinoma metastatic trials by phase

Treatments under study

About Renal Cell Carcinoma Metastatic Clinical Trials

Looking for clinical trials for Renal Cell Carcinoma Metastatic? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Renal Cell Carcinoma Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Renal Cell Carcinoma Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Renal Cell CarcinomaClear Cell Renal Cell CarcinomaKidney Cancers+6 more
Neomorph, Inc30 enrolled7 locationsNCT07300241
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Breast Cancer MetastaticRenal Cell Carcinoma MetastaticProstate Cancer Metastatic+2 more
Kidney Cancer Research Bureau58 enrolled5 locationsNCT07292168
Recruiting
Phase 3

Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)

Renal Cell Carcinoma MetastaticRenal Cell Carcinoma (Kidney Cancer)Kidney Cancer Metastatic
Sun Yat-sen University252 enrolled9 locationsNCT06726421
Recruiting
Not Applicable

Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial

Renal Cell Carcinoma MetastaticKidney CancerSynchronous Neoplasm
Niels Fristrup400 enrolled4 locationsNCT03977571
Recruiting
Not Applicable

Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management

Renal Cell CarcinomaRenal Cell Carcinoma Metastatic
Royal Marsden NHS Foundation Trust24 enrolled1 locationNCT06995664
Recruiting

A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)

Renal Cell CarcinomaRenal Cell Carcinoma Metastatic
St. Antonius Hospital180 enrolled1 locationNCT05548621
Recruiting

TDM for Optimized Outcome in Patients With mRCC.

Renal Cell Carcinoma MetastaticKidney CancerDrug Toxicity+2 more
Niels Fristrup200 enrolled1 locationNCT04659343
Recruiting
Phase 1

A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma

Renal Cell Carcinoma Metastatic
Jemincare80 enrolled1 locationNCT06321250
Recruiting
Not Applicable

The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial

Kidney CancerClear Cell Renal Cell Carcinoma MetastaticSynchronous Neoplasm
Yonsei University40 enrolled3 locationsNCT05753839